Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer

ZNF217 is a candidate oncogene with a wide variety of deleterious functions in breast cancer. Here, we aimed at investigating in a pilot prospective study the association between ZNF217 mRNA expression levels and the clinical response to neoadjuvant endocrine therapy (ET) in postmenopausal ER-positi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Vendrell, Julie A., Solassol, Jérôme, Győrffy, Balázs, Vilquin, Paul, Jarlier, Marta, Donini, Caterina F., Gamba, Laurent, Maudelonde, Thierry, Rouanet, Philippe, Cohen, Pascale A.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355665/
https://ncbi.nlm.nih.gov/pubmed/30740056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.01581
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados